NoBsRx Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 8/10
Best for: shoppers who want every compounded GLP-1 price published before they start an intake
NoBsRx's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the monthly price
Medication
Not stated
Clinician visits
Not stated
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
NoBsRx is an online GLP-1 service that runs its intake on OpenLoop Health's telehealth platform and fills prescriptions through four compounding pharmacies it names in its Terms. Its pitch is price transparency: every program is priced on its site before you start, at the same price at any dose. Compounded semaglutide injections are $179 a month, oral semaglutide $199 and tirzepatide $249, with low-dose programs from $140. The site does not name the company behind it.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to NoBsRx
Editorial score · methodology
Synergy Rx
Best for: knowing which pharmacy fills the vial — it names Belmar Pharmacy
Editorial score · methodology
RxSpan MD
Best for: knowing which pharmacy fills the vial — it names Belmar Pharmacy
Editorial score · methodology
NoBsRx at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide, Oral semaglutide option
- Starting price
- $140/mo (A separate low-dose program, not the standard weight-loss plan. Also sold as $409 for 12 weeks, charged upfront.)
- Pricing model
- Flat — dose increases don't raise the monthly price
- FDA status
- No FDA warning letter on record
How NoBsRx scores
Six columns, each one computed from something NoBsRx has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
9.4/10$140/month is 46% below the register median of $259 for compounded tirzepatide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
6.5/10does not name a dispensing pharmacy; shows a price before asking for health information. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
5.0/10States too little about what the monthly cost covers to score the bundle. Held at the midpoint rather than assumed.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on NoBsRx
Last checked September 2026- Re-read the price on file across 6 dose or plan tiers
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with NoBsRx involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1NoBsRx publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3NoBsRx does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- Cheapest standing monthly prices on record: semaglutide $140, tirzepatide $140. Membership fees, first-month rates and insured copays are excluded from those figures.
- No state list is published, so whether NoBsRx serves your state cannot be confirmed from its site.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
NoBsRx support, as documented
- Phone
- 1-808-518-3894
- support@nobsrx.com
Cancelling NoBsRx
Read from what NoBsRx publishes in its own terms. Where a line says the seller does not publish something, that is the finding — we looked and it is not stated. Terms change; check the seller’s current policy before you subscribe.
- Cancel any time
- Yes
- Minimum commitment
- Month to month, or prepaid 12, 24 or 52-week terms (low-dose programs: month to month or 12 weeks); auto-renews until canceled by email before the renewal date
- Refund policy
- "Subscription fees for the current billing period are generally non-refundable once a billing period has begun."
- Early-termination fee
- None
GLP-1 medications NoBsRx offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Same price at every dose. You can also prepay $499 for 12 weeks, $999 for 24 weeks or $1,899 for 52 weeks, each charged upfront. Twelve weeks is 84 days, a little less than three calendar months.
Same price at every dose. Prepay options are $579 for 12 weeks, $1,149 for 24 weeks or $2,199 for 52 weeks, charged upfront. NoBsRx does not say whether the oral form is a tablet, drops or a dissolving film.
Same price at every dose. Prepay options are $649 for 12 weeks, $1,289 for 24 weeks or $2,599 for 52 weeks, charged upfront.
A separate low-dose program, not the standard weight-loss plan. Also sold as $409 for 12 weeks, charged upfront.
A separate low-dose program, not the standard weight-loss plan. Also sold as $409 for 12 weeks, charged upfront.
A separate low-dose oral program. Also sold as $409 for 12 weeks, charged upfront, which works out cheaper than paying monthly.
Check the price yourself before you pay
Every figure here was read off NoBsRx's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Tirzepatide at $140 a month, 46% below the $259 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What NoBsRx charges
NoBsRx charges $140/month, and holds that rate across every dose. That sits at the affordable end of what we track. Flat dose pricing matters more than it reads: on a tiered plan the bill grows as the dose does, which means the figure that persuaded you to sign up is not the figure you end up living with.
- Compounded semaglutide — $179/month
- Compounded semaglutide — $199/month
- Compounded tirzepatide — $249/month
- Compounded semaglutide — $140/month
- Compounded tirzepatide — $140/month
- Compounded semaglutide — $179/month
Across the GLP-1 providers in our register the median standing price is about $170/month, so NoBsRx is genuinely under the middle rather than merely advertising that it is.
HealthRX dispenses semaglutide and tirzepatide from $133/month, which makes it the honest comparison to run before committing here.
What NoBsRx dispenses
NoBsRx prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product — the specific preparation has not been reviewed for safety, efficacy or manufacturing quality.
A needle-free oral option is genuinely uncommon and is the reason some readers will look at NoBsRx at all. Set expectations on the evidence, though: the published weight-loss trials for these molecules used injections. Oral and sublingual delivery of peptides is far less studied, so treat it as a route that solves the needle problem rather than as a demonstrated equal to the shot.
What we could verify
NoBsRx publishes little that can be checked from outside an intake. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- the lowest standing monthly cost is what you are solving for
- you want the price to stop moving as your dose climbs
- injections are the thing keeping you from starting
Our read
NoBsRx competes on price and does it without an obvious sacrifice elsewhere: $140/month, no warning letter on file, and access that is not unusually restricted.
The Bottom Line
NoBsRx's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay NoBsRx
Starting at $140 a month. Check today's price, then book the free consultation.
Where NoBsRx is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
- If you need the FDA-approved pen rather than a compounded vial, consider Found.
- If the standing monthly cost is what decides it, consider Collective (from $59/mo).
- If you want a human checking in, not just a prescription, consider RxSpan MD.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this NoBsRx review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of September 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See NoBsRx's current pricing
Plans start at $140 a month. The free consultation is where you learn whether you qualify, and what it costs today.